Edwards Lifesciences Corp


Market Cap$52.69B

Compare Edwards Lifesciences

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Edwards Lifesciences CorpEdwards Lifesciences Corp37.60%21%9.60.1
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Earnings Call Q4 2023

February 6, 2024 - AI Summary

Edwards Lifesciences reported strong financial performance in 2023, with full-year sales up 12% to $6 billion.
The company achieved better-than-expected Q4 growth of 13%, driven by a broad portfolio of innovative therapies.
In TAVR, the company experienced strong adoption of its SAPIEN 3 Ultra RESILIA platform and completed enrollment in the PROGRESS trial ahead of schedule. They also expect to present data from the EARLY TAVR trial later this year.
In TMTT, Edwards achieved significant milestones with continued global expansion of the PASCAL platform and the introduction of EVOQUE in Europe. EVOQUE recently received FDA approval for the treatment of tricuspid regurgitation patients.
Edwards is committed to bringing differentiated therapies to patients with mitral and tricuspid disease and believes their strategy positions them well for leadership in the space.

Current Fair Value

3% upside

Undervalued by 3% based on the discounted cash flow analysis.

Share Statistics

Market cap$52.69 Billion
Enterprise Value$51.64 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$2.3
Outstanding Shares601,300,000
Avg 30 Day Volume4,809,206


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio37.57
Price to Sales9.61
Price to Book Ratio7.86
Enterprise Value to Revenue8.6
Enterprise Value to EBIT29.89
Enterprise Value to Net Income36
Total Debt to Enterprise0.01
Debt to Equity0.09

Revenue Sources

No data

ESG Score

No data

About Edwards Lifesciences Corp

CEO: Michael Mussallem